Paul Gurbel to Male
This is a "connection" page, showing publications Paul Gurbel has written about Male.
Connection Strength
0.130
-
Thrombogenicity markers for early diagnosis and prognosis in COVID-19: a change from the current paradigm? Blood Coagul Fibrinolysis. 2021 Dec 01; 32(8):544-549.
Score: 0.013
-
Bedside thromboelastography to rapidly assess the pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population. J Thromb Thrombolysis. 2021 May; 51(4):902-904.
Score: 0.013
-
"Blueprinting" thrombogenicity and antithrombotic drug response at the bedside in patients presenting emergently with symptoms of acute stroke. J Thromb Thrombolysis. 2019 Feb; 47(2):192-199.
Score: 0.011
-
Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study. J Thromb Thrombolysis. 2018 May; 45(4):469-476.
Score: 0.010
-
Platelet Inhibition and Bleeding in Patients Undergoing Non-Cardiac Surgery-The BIANCA Observational Study. Thromb Haemost. 2018 05; 118(5):864-872.
Score: 0.010
-
Thromboxane inhibition during concurrent therapy with low-dose aspirin and over-the-counter naproxen sodium. J Thromb Thrombolysis. 2018 Jan; 45(1):18-26.
Score: 0.010
-
Thrombogenicity and central pulse pressure to enhance prediction of ischemic event occurrence in patients with established coronary artery disease: The MAGMA-ischemia score. Atherosclerosis. 2018 01; 268:55-62.
Score: 0.010
-
Low-density lipoprotein 4: a novel predictor of coronary artery disease severity. Curr Med Res Opin. 2017 11; 33(11):1979-1984.
Score: 0.010
-
Central aortic pulse pressure, thrombogenicity and cardiovascular risk. J Thromb Thrombolysis. 2017 Aug; 44(2):223-233.
Score: 0.010
-
Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system. J Thromb Thrombolysis. 2017 May; 43(4):437-445.
Score: 0.010
-
Ion channel inhibition against COVID-19: A novel target for clinical investigation. Cardiol J. 2020; 27(4):421-424.
Score: 0.003
-
Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. Eur Heart J Cardiovasc Pharmacother. 2020 07 01; 6(4):203-210.
Score: 0.003
-
Influence of Amlodipine on Haemostatic Measurements during Clopidogrel Treatment in Patients with Coronary Artery Disease. Thromb Haemost. 2019 Feb; 119(2):264-273.
Score: 0.003
-
Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population. Circ Cardiovasc Interv. 2018 10; 11(10):e006853.
Score: 0.003
-
Outcomes of Patients Receiving Downstream Revascularization After Initial Medical Management for Non-ST-Segment Elevation Acute Coronary Syndromes (From the TRILOGY ACS Trial). Am J Cardiol. 2018 10 15; 122(8):1322-1329.
Score: 0.003
-
Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis. Arterioscler Thromb Vasc Biol. 2018 06; 38(6):1368-1380.
Score: 0.003
-
Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. JACC Cardiovasc Interv. 2017 08 28; 10(16):1607-1617.
Score: 0.002
-
Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction: The REMODELING Trial. Thromb Haemost. 2017 05 03; 117(5):911-922.
Score: 0.002
-
Relationship between age and platelet activation in patients with stable and unstable angina. Arch Gerontol Geriatr. 2009 Mar-Apr; 48(2):155-9.
Score: 0.001